Fig 1: Murine and human tumor express high levels of FcyRIIB in the tumor microenvironment.A) Table demonstrating the relative binding affinities of ipilimumab or tremelimumab subclasses for activating and inhibitory FcyRs.B) Characterization of human FcyR expression in spleen or tumor infiltrating leukocytes. Each hFcyR was evaluated using flow cytometry of dissociated tissues.C) mIF of human tissue samples for hFcyRIIIA (CD16) and FcyRIIB (CD32B) on infiltrating myeloid cells using the PhenoImager HT.D) Quantification of CD32B and CD16 expression on tumor infiltrating CD68+ myeloid cells and ratio of staining of the activating (CD16) and inhibitory (CD32B) profile.